CT-ATLAS-HOLDINGS
30.9.2020 11:17:07 CEST | Business Wire | Press release
Atlas Holdings announced today that it has completed its acquisition of Permasteelisa Group, a global leader in the engineering, project management, manufacturing, installation and after-sales service of advanced building facades, architectural envelopes and interiors. Permasteelisa Group has partnered with architects on more than 3,500 projects that have transformed skylines around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005357/en/
Permasteelisa Group’s three brands, Permasteelisa, Gartner and Scheldebouw, are recognized as the premier integrated providers of high quality, bespoke curtain wall solutions in the world. Collectively, the company employs more than 4,500 associates, designing, fabricating and installing premier projects out of locations in 30 countries, including nine production facilities and eight principal design offices.
“Permasteelisa Group is trusted by the world’s most visionary architects to turn their designs into reality and has a 100 percent project delivery record over its five decades of market leadership. Combining this unique positioning in the market with Atlas’ construction and manufacturing industry expertise is a ‘win-win’ for the company, its associates and its customers,” said Timothy Fazio, Atlas Holdings Co-Founder and Managing Partner. “We are thrilled to welcome Permasteelisa Group to the Atlas Family.”
“Permasteelisa Group has brought to life some of the world’s most iconic buildings,” said Peter Bacon, Operating Partner of Atlas Holdings. “The company’s ability to execute large, complex projects is simply unmatched in the curtain wall industry.”
Permasteelisa Group’s notable projects include the Shard in London, Apple’s HQ campus in Cupertino, the World Trade Center redevelopment in New York, where the group worked on 1WTC, 3WTC and 7WTC, the World Financial Center in Shanghai, New York City’s One Vanderbilt and the International Commerce Center in Hong Kong.
“We could not have found a better partner to strengthen our company today and build a brighter future than Atlas Holdings,” said Klaus Lother, Permasteelisa Group Chief Executive Officer. “Our clients trust us to get the job done quickly and flexibly, wherever a project demands, and Atlas’ global footprint and directly relevant experience in the construction and manufacturing arenas is a perfect fit. Most importantly, they have a long-term focus and share our core values; a commitment to environmental stewardship, employee safety and delivering superior customer service. Our team is thrilled to begin working with Atlas.”
###
About Atlas Holdings
Headquartered in Greenwich, Connecticut and founded in 2002, Atlas and its affiliates own and operate 22 platform companies which employ more than 25,000 associates at more than 200 facilities worldwide. Atlas operates in sectors such as aluminum processing, automotive, building materials, capital equipment, construction services, food manufacturing and distribution, packaging, paper, power generation, pulp, supply chain management and wood products. Atlas’ companies together generate more than $6 billion in revenues annually. For additional information, please visit www.atlasholdingsllc.com .
About Permasteelisa Group
The Permasteelisa Group operates worldwide in the design, production and installation of architectural enclosures, curtain walls and interior systems, placing itself in a position of absolute leadership in the global reference market. In all of its projects the Group contributes with its Know-How and its experience, especially for the "Special Features Buildings," from the design phase to the successful completion, reaching the architectural expectations of its customers. Among the Group's achievements, there are some of the most prestigious contemporary architectural works in the world such as the Sydney Opera House (the first building to use the curtain wall system extensively), Eight Spruce in lower Manhattan (also known as Beekman Tower), The Shard and 20 Fenchurch Street in London, the revolutionary Guggenheim Museum in Bilbao, the extraordinary Walt Disney Concert Hall in Los Angeles and the MoMA in New York. To discover more, please visit www.permasteelisagroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005357/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
